{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:52:44Z","timestamp":1767826364289,"version":"3.49.0"},"reference-count":111,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.1080\/10428194.2017.1300898","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T14:36:33Z","timestamp":1490020593000},"page":"2275-2286","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Novel agents in classical Hodgkin lymphoma"],"prefix":"10.1080","volume":"58","author":[{"given":"Sven","family":"Borchmann","sequence":"first","affiliation":[{"name":"German Hodgkin Study Group (GHSG), Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"German Hodgkin Study Group (GHSG), Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"CIT0001","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (http:\/\/seer.cancer.gov\/data\/); 2015."},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61469-0"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5807"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000314"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.1180"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3721"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30093-6"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.7450"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-681064"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4181"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8246"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07740.x"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"CIT0019","unstructured":"Phase 3 frontline therapy trial in patients with advanced classical Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT01712490; 2016."},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.018"},{"key":"CIT0022","unstructured":"Phase I\/II feasibility study combining brentuximab vedotin with second line salvage chemotherapy (DHAP) in Hodgkin lymphoma patients \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02280993; 2016."},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V128.22.1109.1109","volume":"128","author":"Garcia-Sanz R","year":"2016","journal-title":"Blood"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-644336"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397893"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","volume":"126","author":"LaCasce AS","year":"2015","journal-title":"Blood"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.587.587"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2101-4"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1107.1107"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70265-0"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.38"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.608448"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.003"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5223"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4443.4443"},{"key":"CIT0047","volume-title":"JAK\u2013 inhibition in recurrent classical Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02164500","year":"2016"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-014-0091-4"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13152"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.1.131"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13603"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0770"},{"key":"CIT0054","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","volume":"85","author":"Johnston PB","year":"2010","journal-title":"Am J Hematol"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2740.2740"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1906"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.11.019"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.05.012"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5304"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07963.x"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-362475"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1007212"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2129"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8401"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1845"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391037"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008484206680"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12630"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.744453"},{"key":"CIT0072","volume-title":"Everolimus in combination with DHAP in patients with relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT01453504","year":"2016"},{"key":"CIT0073","volume-title":"HD21 for advanced stages \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02661503","year":"2016"},{"key":"CIT0074","volume-title":"A Phase II study of brentuximab vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease. Full text view \u2013 ClinicalTrials.gov Identifier: NCT02227433","year":"2016"},{"key":"CIT0075","volume-title":"Mocetinostat (MGCD0103) plus brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02429375","year":"2016"},{"key":"CIT0076","volume-title":"Study of rituximab and brentuximab vedotin for relapsed classical Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT01900496","year":"2016"},{"key":"CIT0077","volume-title":"Brentuximab vedotin and bendamustine for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT01657331","year":"2016"},{"key":"CIT0078","volume-title":"Brentuximab vedotin plus AD in non-bulky limited stage Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT02505269","year":"2016"},{"key":"CIT0079","volume-title":"Everolimus and brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02254239","year":"2016"},{"key":"CIT0080","volume-title":"A pilot trial of AVD and brentuximab vedotin (SGN-35) in the treatment of stage III\u2013IV HIV\u2013associated Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02298257"},{"key":"CIT0081","volume-title":"Brentuximab vedotin, ifosfamide, carboplatin, and etoposide in treating patients with relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02227199","year":"2016"},{"key":"CIT0082","volume-title":"Ibrutinib and brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02744612","year":"2016"},{"key":"CIT0083","volume-title":"Brentuximab vedotin and combination chemotherapy in treating patients with stage II\u2013IV HIV\u2013associated Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT01771107","year":"2016"},{"key":"CIT0084","volume-title":"Brentuximab vedotin in refractory\/relapsed Hodgkin lymphoma treated by ICE \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02686346","year":"2016"},{"key":"CIT0085","volume-title":"Brentuximab vedotin associated with chemotherapy in untreated patients with Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT02292979"},{"key":"CIT0086","volume-title":"Brentuximab for newly diagnosed Hodgkin disease \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02398240","year":"2016"},{"key":"CIT0087","volume-title":"Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02191930","year":"2016"},{"key":"CIT0088","volume-title":"Brentuximab vedotin as consolidation treatment in patients with stage I\/II HL and PET positivity after 2 cycles of ABVD. ClinicalTrials.gov Identifier: NCT02298283","year":"2016"},{"key":"CIT0089","volume-title":"Brentuximab vedotin combined with AVD chemotherapy and involved-site radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT01868451","year":"2016"},{"key":"CIT0090","volume-title":"Immunotherapy following reduced intensity conditioning and allogeneic stem cell transplant for poor risk CD30+ Hodgkin lymphoma patients \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02098512","year":"2016"},{"key":"CIT0091","volume-title":"A phase II study with bendamustine plus brentuximab vedotin in Hodgkin\u2019s lymphoma and CD30+ peripheral T-cell lymphoma in first salvage setting: the BBV regimen \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02499627","year":"2016"},{"key":"CIT0092","volume-title":"Hodgkin lymphoma treatment with adcetris and levact in the old patient \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02467946","year":"2016"},{"key":"CIT0093","volume-title":"Study of REGN2810 and REGN1979 in patients with lymphoma or acute lymphoblastic leukemia \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02651662","year":"2016"},{"key":"CIT0094","volume-title":"Avelumab in patients with previously treated advanced stage classical Hodgkin\u2019s lymphoma (JAVELIN HODGKINS) \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02603419","year":"2016"},{"key":"CIT0095","volume-title":"Safety & efficacy study of combination of pembrolizumab and lenalidomide, in patients with relapsed non-Hodgkin and Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02875067","year":"2016"},{"key":"CIT0096","volume-title":"Pilot study of pembrolizumab treatment for disease relapse after allogeneic stem cell transplantation \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02981914","year":"2016"},{"key":"CIT0097","volume-title":"Pembrolizumab in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02595866","year":"2016"},{"key":"CIT0098","volume-title":"ACP-196 (acalabrutinib) in combination with pembrolizumab, for treatment of hematologic malignancies \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02362035","year":"2016"},{"key":"CIT0099","volume-title":"A study of brentuximab vedotin combined with nivolumab for relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02572167","year":"2016"},{"key":"CIT0100","volume-title":"Ibrutinib and nivolumab in treating patients with relapsed or refractory classical Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02940301","year":"2016"},{"key":"CIT0101","volume-title":"Ipilimumab, nivolumab, and brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT01896999","year":"2016"},{"key":"CIT0102","volume-title":"Nivolumab and brentuximab vedotin in treating older patients with untreated Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT02758717","year":"2016"},{"key":"CIT0103","volume-title":"A study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204) \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02327078","year":"2016"},{"key":"CIT0104","volume-title":"Nivolumab with or without ipilimumab in treating younger patients with recurrent or refractory solid tumors or sarcomas \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02304458","year":"2016"},{"key":"CIT0105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"CIT0106","volume-title":"Study of the combination of AFM13 and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02665650","year":"2016"},{"key":"CIT0107","volume-title":"Study of pembrolizumab (MK-3475) vs. brentuximab vedotin in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-204\/KEYNOTE-204) \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02684292","year":"2016"},{"key":"CIT0108","volume-title":"Nivolumab with Epstein\u2013Barr virus specific T cells (EB-VSTS), relapsed\/refractory EBV positive lymphoma (PREVALE) \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02973113","year":"2016"},{"key":"CIT0109","volume-title":"A study of CA-170 (Oral PD-L1, PD-L2 and VISTA checkpoint antagonist) in patients with advanced tumors and lymphomas \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02812875","year":"2016"},{"key":"CIT0110","volume-title":"Pembrolizumab after ASCT for Hodgkin lymphoma and DLBCL \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02362997","year":"2016"},{"key":"CIT0111","volume-title":"A study of nivolumab\u2009+\u2009brentuximab vedotin in children, adolescents, and young adults with classic Hodgkin lymphoma (cHL) after failure of first line therapy, followed by brentuximab vedotin\u2009+\u2009bendamustine for participants with a suboptimal response \u2013 full text view \u2013 ClinicalTrials.gov Identifier: NCT02927769","year":"2017"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2017.1300898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T04:06:03Z","timestamp":1719115563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2017.1300898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["10.1080\/10428194.2017.1300898"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2017.1300898","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}